A slower-than-usual year for medtech M&A in 2023 was reflected in relatively few company exits from the Top 100 annual listing of publicly traded device, diagnostics and healthtech companies by re
A slower-than-usual year for medtech M&A in 2023 was reflected in relatively few company exits from the Top 100 annual listing of publicly traded device, diagnostics and healthtech companies by re
Becton, Dickinson and Company chair, CEO and president Tom Polen was clear about the medtech industry’s contribution to the ongoing transformation of health care. Speaking to delegates on the opening
While leading medical device companies, notably Johnson & Johnson , scored revenue gains in 2023, for in vitro diagnostics manufacturers it was largely a different story. The COVID-19 bubble for medt